M. Zola

Discipline

Psychology (4)

Type

Articles (10)

Co-author

Date

Source

Keyword

Patients (9) Patients (9) Retinal (Visual pigment) (8) Retinal degeneration (7) Eye (7) Treatment (6) age (5) Human beings (5) Age (5) Age (5) therapy (4) association (4) need (4) disease (4) Visual acuity (4) Tomography (4) Therapeutics (4) Social groups (4) Multivariate analysis (4) Months (4) Injections (4) Older people (4) Tomography (4) disease (4) analysis (3) dosage (3) Inhibitors (3) Neovascularization (3) Manufacturers' agents (3) Growth (3)

Documents written by M. Zola (10) | is about M. Zola (0)

Short-term response to anti-VEGF as indicator of visual prognosis in refractory age-related macular degeneration.
A. Gigon et al.
High Levels of C-Reactive Protein with Low Levels of Pentraxin 3 as Biomarkers for Central Serous Chorioretinopathy.
E. Bousquet et al.
EVIDENCE AGAINST A CONTRALATERAL COATS PHENOTYPE BY OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY.
A. Daruich et al. (Jun 1, 2022)
Refractory neovascular age-related macular degeneration: time-dependent changes of central retinal thickness with anti-VEGF treatment.
M. Zola et al.
Oral Ursodeoxycholic Acid Crosses the Blood Retinal Barrier in Patients with Retinal Detachment and Protects Against Retinal Degeneration in an Ex Vivo Model.
A. Daruich et al.
Lipocalin 2 as a potential systemic biomarker for central serous chorioretinopathy.
A. Matet et al. (Nov 19, 2020)
Resolution of Corneal Fibrosis After Descemet's Stripping Automated Endothelial Keratoplasty: A Case Report.
M. Zola et al.
Antidepressant medication and ocular factors in association with the need for anti-VEGF retreatment in neovascular age-related macular degeneration.
I. Mantel et al.
MACULAR ATROPHY INCIDENCE IN ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR-TREATED NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: Risk Factor Evaluation for Individualized Treatment Need of Ranibizumab or Aflibercept According to an Observe-and-Plan Regimen.
I. Mantel et al.
Two-year outcome of an observe-and-plan regimen for neovascular age-related macular degeneration treated with Aflibercept.
P. Parvin et al.